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Adeno-associated viruspatients with hepatitis B virus (HBV) infection is associated with a high rate of
graft loss and poor survival, unless re-infection can be prevented. Human hepatitis B immune globulin (HBIG)
and nucleoside analogues (NA) have long been utilized to prevent re-infection. Previously, we generated a
human monoclonal antibody (mAb), HB that recognizes the surface antigen of hepatitis B virus (HBV). We
have constructed a secreted version of HB and cloned its genes into recombinant adeno-associated virus
(AAV). We compared the efﬁciency of AAV vector after a single injection via intramuscular or intravenous
routes without additional intervention. Then, we evaluated the activity of antibody HB in tree shrews treated
with rAAV-HB and in vitro experiments. So, intramuscular injection of rAAV-HB was a suitable method for
the immunoprophylaxis of HBV infection. This human antibody will be useful for the immunoprophylaxis of
HBV infection.
© 2008 Published by Elsevier Inc.Chronic hepatitis B virus (HBV) infection occurs worldwide, and
more than 10% of the population in hyper endemic areas such as
Southeast Asia, China, and Africa are HBV carriers (Andre, 2000; Kane,
1996). The patients infected with Hepatitis B virus (HBV) may incur
chronic hepatitis, cirrhosis, and hepatocellular carcinoma (Blum et al.,
1998). Liver transplantation (LT) has become a successful surgical
therapy for those terminal liver diseases. However, recurrence of HBV
infection after LT plays a key role for the outcome after liver
transplantation concerning patient and graft survival rates (Fresh-
water et al., 2008).
It was reported that HBV recurrence after LT is signiﬁcantly
reduced by prophylaxis with hyper immune antibody to hepatitis B
surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs
(Muller et al., 1991;Tchervenkov et al., 1997;Schiff et al., 2007;
Anderson et al., 2007; Ołdakowska et al., 2007). Low-dose intramus-
cular HBIG protocols have yielded cost reduction by N50%. However,
HBIG is still expensive and requires close monitoring of the LT patient.
HBIG is prepared from the sera of antibody positive donors and its
safety is assured by strict product standards (Habib and Shaikh, 2007;
Lo et al., 2003; Brown and Moonka, 2000; Shouval and Samuel, 2000;
Muller et al., 1991). Therefore, the currently available HBIG is not an
ideal source of therapeutic antibody due to its limited availability, low.
lsevier Inc.speciﬁc activity and possible contamination of infectious agents
(Ehrlich et al., 1992; Witherell, 2002). HBIG-free therapeutic regimens
with new promising nucleos (t) ide analogue combinations are
currently being investigated for their efﬁcacy and safety as ﬁrst-line
therapy in clinical studies (Wong et al., 2007). Therefore, adoptive
gene transfers of immunity against HBV, HBV vaccines and donor-
derived immunity need to be elucidated (Cofﬁn and Terrault, 2007;
Beckebaum et al., 2008).
The genetically engineered monoclonal antibodies (mAbs) speciﬁc
to the surface antigens of HBV would be a good alternative for the
immunoprophylaxis of HBV infection (Hong et al., 2004) andmay have
the potential to resolve these problems. Therefore, Fab fragments are
particularly important for a wide variety of applications, including
detection and treatment of human diseases (Levy and Miller, 1983), in
vitro diagnostic test (Tam and Goldstein, 1985) and afﬁnity puriﬁca-
tion methods (Johnstone and Thorpe, 1982). Because of the absence of
the Fc fragment, they are low-molecular-weightmolecules with a high
degree of speciﬁcity, so they easily localize to the target and are
rapidly cleared without accumulation in the tissues (Protzer-Knolle et
al., 1998; Trautwein, 2004). So, anti-HBsAg Fab fragment has a
considerable potential in the prevention and treatment of liver
diseases caused by HBV.
Therefore, we cloned the gene of a high afﬁnity antibody,
which came from human peripheral blood. In the previous report,
human Fabs against HBsAg were selected from phage-displayed
antibody library which was constructed using peripheral blood
lymphocytes from vaccinated volunteers. The Fab antibody (named
2 T. Pan et al. / Virology 382 (2008) 1–9as HB) gene was inserted to prokaryotic expression vector p3HB.
The afﬁnity of HB by competition ELISA was 0.5×109 M−1 (Yan et
al., 2000). The antibody showed neutralizing activity against the Ad
subtypes of the virus in an in vitro infection of adult human
hepatocyte primary culture by HBV (Tao et al., 2006; Tao et al.,
2007). In this study, we have constructed the rAAV-HB, investi-
gated and selected the vector delivery methods, and evaluated its
activity. Whereas the gene therapy with rAAV-HB by muscular
injection is considered as an effective treatment for immunopro-Fig. 1. (A) Schematic representation of the strategy for building pXXUF1-HB. The heavy chain
were cloned in the vector pGEM-T. The fusion Fd fragment and the fusion K fragment were
fragments. The genes ofHBwere cloned into pXXUF1. (B) The pXXUF1-HB is identiﬁed byenzy
I+ Mul I; 3. pXXUF1-HBs-Fab/Xba I+Sal I; 4. pXXUF1-HBs-Fab/Not I+Sal I; 5. PCR: pXXUF1
shows that the target genes are successfully cloned into pXXUF1. (C) Nucleotide sequences of
underlined. Nucleotide sequences and derived amino acid sequence of the human anti-HBs-phylaxis of HBV infection, the human antibody HB will be poten-
tially useful.
Results and discussion
Establishment of AAV producing human anti-HBsAg antibody HB
To construct the eukaryotic secreting HB, the cDNA encoding the
light chain and the heavy chain of HB, were cloned from pH3B andand light chain of Fabwere fused with LH by overlap PCR. The resulting fusion fragments
connected by pIRES after one ribosome-binding site for stable expression of both the
me cutting and PCR.M.1 kbDNA ladder";; 1. pXXUF1-HBs-Fab";; 2. pXXUF1-HBs-Fab/Not
-HBs-Fab/5F+3F; 6. PCR: pXXUF1-HBs-Fab/5K+3K; 7. PCR: pXXUF1-HBs-Fab/5F+3K. It
the heavy chain (c1) and light chain (c2) of HB antibody. The added leader sequences are
Fab VH and VL are dashed. The sequence in the AAV remains same with the one in p3HB.
Fig. 1 (continued).
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and Kozak sequence (Kozak, 1981) were added for eukaryotic
secreting expression, before the VH and VL of HB (Fig. 1A). The virus
shuttle plasmid, pXXUF1-HB was constructed and identiﬁed by blue-
white colony screening, restriction enzyme, and sequencing (Figs. 1A,
B). The sequence analysis indicated that the VH belongs to human
heavy chain subgroup III. The sequence of leading, heavy chain Fd and
light chain K of HB, are indicated by restriction enzyme and PCR (Fig.
1C). The VH was the most homologous to human germ line Dxp'1-DK1
and JH6, while the VL belongs to human light chain subgroup I andwas
the most homologous to JK4.
The recombinant adeno-associated virus (rAAV) vectors offermany
unique advantages over other vectors, including its stable transduc-
tion and long-term expression of transgene, the ability to infect both
the dividing and nondividing cells, the lack of pathogenesis or
inﬂammatory response, which are very important requirements for
the treatment of long-term such as prophylaxis to HBV recurrence
after liver transplantation. The AAV vectors were generated by triple
plasmid transfection of 293 cells, as described previously (Xiao et al.,
1998). The titers of rAAV-HB were more than 1012 v.g., which
determined by a standard dot-blot assay.
We selected an antibody against HBsAg of the adr type that is
common in China (Chen et al., 2003). Many researches into anti-HBsAg Fab antibody are limited in antibody library construction,
bacterial E. coli expression, yeast fungus expression, and vegetal cell
expression (Boder and Wittrup, 2000; Becker et al., 1994; Zheng et al.,
2004; Shin et al., 2007). Moreover, the usagewas also limited to purify
them for an injecting usage (Hong et al., 2004). Therewere few reports
on theway of applied antibody.We believe that, through gene transfer
the body to produce antibodies can be used to autonomy for the
prevention and treatment of hepatitis B recurrence of infection. So,
studies of cloning anti-HBsAg Fab antibody into AAV for gene therapy
of HBV recurrence after liver transplantation are preferred. In the
above experiment, the modiﬁed antibody HB genes were successfully
cloned into AAV for secreting expression in vivo.
Comparison of two different transfect ion methods
Different AAV vectors exhibiting distinct tissue tropism and
interacting with different cellular receptors (Summerford and
Samulski, 1998; Di et al., 2003), and gene delivered by liver perfusion
in liver transplantation were considered. To deliver the target genes
into most and evaluate the methods of vector application, we
compare two different transfect methods (intramuscular injection
and portal vein injection) in adult mice. Fused GFP expression driven
by the CMV promoter was used to monitor short- and long-term
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quantitative ﬂuorescent microscopy. We observed a wide range of
gene transfer efﬁciencies 4 months after injection of rAAV-GFP
vectors in C57BL/6 by the two different methods. Using intramuscular
injection — treated mice exhibited stronger GFP expression in the
skeletal muscles examined (Fig. 2A) than all other tissues. Componly
the hind limbs, but also the remote sites such as heart, lung, kidney,
spleen, and liver for a long time (Fig. 2A). Weaker signals were
detected in the left sites except the liver tissues by the portal vein
perfusion (Fig. 2B). In the long-term observation, muscular injection
also gained an advantage over the portal vein perfusion in the mass
(Fig. 2B).
The transfecting methods, the HB expression quantity and
duration were signiﬁcant for therapy to HBV recurrence after liver
transplantation. As usual, two kinds of gene delivery methods are
thought about. One is that recipients are transfected; the other is that
the liver graft is transiently transfected by portal vein perfusion. So we
chose two methods and compared them in the above-mentioned
experiment. It was found that the method transfected by portal vein
perfusionwas in favor of liver tissue. If the antibody HB is expressed in
liver graft, it promotes the protection to the liver. It would be an
efﬁcient method, but the time of transient transfectionwas important
and needs to be most prolonged. On the other hand, the method
transfected by the portal vein perfusion made weaker transfection
efﬁciency than muscular injection. The reason maybe is that theFig. 2. Systemic gene deliveries to C57BL/6 mice by rAAV-GFP via two different injections. (
tissues at 4 months after muscular injection and portal vein injection of 1011 v.g. of rAAV-G
muscle bymuscular injection, and minimal to undetectable GFP expression in the tissues exc
lung, kidney, spleen, liver and muscle cryosections of mice, which were injected i.m. and i.v.
transduced not only the hind limbs, but also the remote sites for a long time. Weaker sign
(C) Quantiﬁcation of GFP ﬂuorescence in liver and muscles by the two different injections of r
advantage over the portal vein perfusion in the mass.metabolism of AAV in serum causes low volume delivery, while
intramuscular injection delivered the antibody genes into most.
Moreover, the AAV vectors were serotype I, which are highly efﬁcient
in transducing muscles. Therefore, a single muscular injection of
rAAV-HB, a simple safe and effective method was selected to do the
further research.
The expression of HB by muscle injection with rAAV-HB
The quantity of HB in serum is signiﬁcant to prevent HBV
recurrence of liver transplantation. The aim of our study was to
determine the expression efﬁcacy of HB after rAAV-HB transfer to
animals by intramuscular injection and observe whether this
transfection has an undesirable side effect. The antibodies, HB levels
in serum of mice treated with rAAV-HB at different titers and Sodium
Chloride were measured by immunoﬂuorometric assay. No HB was
detected in serum of control mice. After intramuscular injection of
1011 v.g. of rAAV-HB, the serum level of HB reached 223.38 mIU/ml in
7 weeks and the level had been maintained in about 100 mIU/ml until
the end of the experiment (Fig. 3A). Therefore, the serum level of HB
wasmaintained above 30mIU/ml until the experimental endingwhen
treatedwith 109 v.g. of rAAV-HB. As well, the HB in serum treated with
1011 v.g. of rAAV-HB show higher levels than other three group treated
with rAAV-HB of different titers, which are parallel to the serum levels
in all the duration of the experiment. The serum levels of mice treatedA) GFP expression seen in cryosections of heart, lung, kidney, spleen, liver, and muscle
FP. The microscopy exposure time of all pictures is 10 s. Note strong GFP expression in
ept liver by portal vein injection. (B) Quantiﬁcation of average GFP ﬂuorescence in heart,
with 1011 v.g. of rAAV-GFP for 4 months. It notes that intramuscular injection effectively
als were detected in the left sites except the liver tissues by the portal vein perfusion.
AAV-GFP at eachmonth. In the long-term observation, muscular injection also gained an
5T. Pan et al. / Virology 382 (2008) 1–9with rAAV-HB were signiﬁcantly higher than control mice (Fig. 3A).
The results show that rAAV-mediated gene transfer can drive long-
term and stable expression of the HB gene in vivo.
Expression levels in liver tissue of HB were analyzed by western
bolt after animals were killed and tissue proteinwas extracted. Results
show that signiﬁcant level of expressed tissue HBwas detected in liver
tissues in rAAV-HB-treated mice and expression level was associatedFig. 3. The HB expressionwas deeply observed, after the C57BL/6 mice were transfect with rA
mice after injection of 1011, 1010, 109 v.g. of rAAV-HB. The quantity of HB in serumwas associat
v.g. of rAAV-HB. (B)Western blot analysis of HB in liver tissues at 4months after i.m. injection
of trace density value of Western blot analysis in liver tissues follows. It shows difference b
connected with the virus quantity. (C) Immunohistochemistry analysis of HB in liver tissues
limbs at 4 months after i.m. injection of 1011 v.g. of rAAV-HB. It shows that HB can be express
the leg muscle than in liver tissue under the same transfecting concentration.with the virus vector titers. However, the HB can be detected in liver
tissues treated with 109 v.g. of rAAV-HB by western blot (Fig. 3B). The
HB levels in liver tissues are detected by immunohistochemistry
paralleled to the level by western blot. The expression level in muscle
is the highest and all other tissues are slightly lower. In control
animals, no HB was detected in liver tissues treated with rAAV-GFP
(Fig. 3C).AV-HB by intramuscular injection. (A) Time course of HB expression in serum of C57BL/6
ed with the viral titers and can be kept more than 30 mIU/ml when transfected with 109
of 1011,1010,109 v.g. of rAAV-HB vectors and 1011 v.g. of rAAV-GFP vectors. Quantiﬁcation
etween the rAAV-HB groups with rAAV-GFP group. The quantity of HB in liver tissue is
at 4 months after i.m. injection of 1011, 1010, and 109 v.g. of rAAV-HB vectors, and in hind
ed in liver tissue even treated with 109 v.g. of rAAV-HB. Greater expression is detected in
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antibodies reached after vaccination has been proposed to be the
lowest limit for protection (Hollinger, 1987). We have detected the
antibody HB titer in serum every week after themicewere transfected
by rAAV-HB. The average titer of HBwasmore than 100mIU/ml during
4 months. These titer anti-HBs antibodies were considered signiﬁ-
cantly reducing the recurrence of HBV infection after liver transplan-
tation. Using single intramuscular injection comes HB gene transfer to
other tissues such as the liver. Lower virus transfer of 109 v.g. of rAAV-
HB, the HB expression was less than other virus concentration after
the transfer of expression, but in this transfer concentration, the HB
expressed in the liver tissues (graft) could be detected and desirable to
protect the graft and increase HBV infection rate.Fig. 4. (A) The course of HBV infection showing the level of anti-HBV antibodies in the
produce antibody peak, after they were infected by HBV. However, those treated with rAA
(B) Immunohistochemical staining of HB-positive tissues with Fab antibodies (original
immunohistochemically with (B1) HB, 7 mg/ml (B2) monoclonal anti-HBs mouse antibody (1
7 mg/ml makes higher afﬁnity to infected tissues than the clinic commercial antibody (1:5
membranes due to HB-mediated complement killing. Cells did not dye by eosin because of tIn vivo virus-clearing activity of HB in tree shrews
Twenty tree shrews were divided into three groups and received
immunosuppressant FK506 at 0.1 mg/d till the end of the experiment.
The study tree shrews were given a single intramuscular injection of
5×1011 v.g. of rAAV-HB and 14 days later, the animals were challenged
with 105 copies/ml of human sera containing wild type HBV (adr
subtype), while the control tree shrews were given an intramuscular
injection of 5×1011 v.g. of rAAV-GFP and only challenged with the
same dose of the virus. The tree shrews were only given a single
intramuscular injection of 5×1011 v.g. of rAAV-HB as another control
group. The course of HBV clearing in the tree shrewswasmonitored by
serological and biochemical analyses of the sera. In the case of theserum of three groups: it shows that the tree shrews treated with rAAV-HB did not
V-GFP produce antibody peak by immunoreactions, after they were infected by HBV.
magniﬁcation ×200).Thin-sectioned HB-positive biopsied liver tissues were stained
:50 dilution) as positive control, or (B3) anti-HCMV Fab antibody. It shows that the HB at
0 dilution). (C) Quantiﬁcation of killed cells. Cells dyed by eosin because of fracture of
he integrity of cells' membranes without HB-mediated complement killing.
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near 5–7th day and elevated serum levels of liver enzymes (alanine
aminotransferase and aspartate aminotransferase) were detected
from 7–10th day. During this period, using real-time PCR method
can be detected in the blood of HBV-DNA, until the antigen disappears.
Also, actively acquired serum anti-HBc and anti-HBs antibodies
appeared from near the 12th day and 10–14th day, respectively, and
remained at elevated level through the end-point of this experiment.
The necrosis and lymphomonocyte inﬁltrations existed in the liver
tissues till the end of the experiment.
In contrast, in the case of the study tree shrews, neither HBsAg
increased peak nor actively acquired anti-HBV antibody was detected
during the experiment, while the administered human antibody was
detected. The antibody had a low level compared to that without HBV
injection (Fig. 4A). This may be because the HB bound to the
challenged HBV were eliminated from the blood of the challenged
tree shrews. The liver tissues were normal after 1 month. The results
indicate that the HB neutralized the HBV in vivo and thus protected
the tree shrews from the attack of HBV.
Binding of HB to human tissues
To analyze the immunohistochemical staining characteristics of
Fab clones, each Fab antibody should incubate with a liver biopsy
sample expressing HBs antigen. As a positive control, sections were
stained with monoclonal mouse anti-HBs IgG (Fig. 4c2). As shown in
Fig. 4c1, HB similarly stained the section, even though fewer staining
spots were evident, indicating that the monoclonal anti-HBs IgG
contains several kinds of antibody that recognize multiple epitopes of
HBs (ad/ay). In contrast, HB is monoclonal and recognizes a single
epitope. For the negative control shown in Fig. 4B3, there was no
staining when the section was incubated with an anti-HCMV Fab
antibody. The HB antibody does not demonstrate cross reactivity with
the human liver tissues.
HB-mediated micro-cytotoxicity assay
The anti-HBs antibodies have complement-dependent cytotoxicity
in cells expressing HBsAg on their surface. To determine whether HB
possesses the same activity, we used a complement-dependent
cytotoxicity assay. Approximately 97.01429±0.90264% of 1000 treated
Hep3B cells were killed by HB. Human IgG also showed cell lyses
activity. The rate of cell death was 99.1% in the positive control group
and 14.4286±1.9132% in the negative control group (Fig. 4d3). Cell
death rates in the three groups were assessed by the Chi-square test.
There was almost no statistical difference in cell death rate between
the HB inhibition group and the positive control group. But the cell
death rate differed remarkably between the HB inhibition group and
the negative control group.
Hepatitis B virus (HBV), the prototype of the family Hepadnavir-
idae is an organ and species-speciﬁc human pathogen (Neurath et al.,
1986). The restriction of HBV infection to chimpanzees has increased
demand for small HBV animal model (Dandri et al., 2001; Dandri et
al., 2006). Because the tree shrew is phylogenetically related to
primates (Schmitz et al., 2000), the hepatocytes isolated from the
Asian tree shrew Tupaia belangeri have been shown to be susceptible
for HBV infection like primary human hepatocytes (Köck et al., 2003;
Dandri et al., 2005; Köck et al., 2001). It was reported that the tree
shrews can be as human HBV-induced hepatitis animal model
(Walter et al., 1996; Yan et al., 1996; Glebe et al., 2003; Wang et al.,
2003; von Weizsäcker et al., 2004; Yang et al., 2005).Our group are
establishing the animal model for HB research in vivo. In this study,
we ﬁrst demonstrate that anti-S protein mAb is capable of
neutralizing HBV infection in vivo. It is also found that there is a
considerable prophylaxis measure to HBV infection by single
intramuscular injection with rAAV-HB. The antibodies HB wereproduct actively which led to the continuous passive immunity. It
gives out a new gene therapy method instead of traditional
treatment to HBV recurrence after liver transplantation. This study
provides a valid basis for further clinical application research.
Recently, we successfully transplanted a liver in a tree shrew. We
expect that the liver graft transfectionmay be another useful method
to prevent HBV recurrence after liver transplantation.
Statistical analysis
The data were collected from at least three independent experi-
ments. All statistical analyses used SPSS12.0 software (SPSS, Inc.,
Chicago, IL). Descriptive data were expressed as mean±SD. Statistical
signiﬁcance was determined using the Paired t-test and Chi-square
test. The P value less than 0.05 was considered statistically signiﬁcant.
Materials and methods
Construction of vectors for HB expression
The HBs-Fab clone, which was selected from phage library (Yan et
al., 1995), was inserted to prokaryotic expression vector. The vectors
for expression of antibody were derived from the p3HB (a generous
gift from Dr Yan Wang) for heavy chain Fd and light chain K.
The heavy chain Fd gene sequences were ampliﬁed by polymerase
chain reaction (PCR) using primers LH (CCC AGA TAC CAC TGG AGA
GGT GCA GCT GCT CGA) and 3F (GGT ACG CGT TTA TTT GTC ACA AGA
TTT GGG C) on the p3HB and the light chain K using primers LK (CCC
AGA TAC CAC TGG AGA GCT CAC GCA GTC TCC) and 3K (TGC GTC GAC
TTA CTA ACA CTC TCC CCT GTT G) on the p3HB.
The leader DNA sequence was synthesized by PCR using primers
LH1 (GAA GCC CCA GCG CAC GTT CTC TTC CTC CTG CTA CTC TGG CTC
CCA GAT ACC ACT GGA) and LH2 (CTT CGG GGT CGC GTG CAA GAG
AAG GAG GAC GAT GAG ACC GAG ACC GAG GGT CTA TGG TGA CCT).
The product LH were preserved at −20 °C.
The SF and SKwere synthesized by overlap PCR using LH and F, K as
template and four synthetic oligonucleotides as PCR primers. The
nucleotide sequences of the PCR primers are the following: 5F: (GAC
CGC TAG CGG CCG CCA TGG AAG CCC CAG CGC AC); 3F: (GGT ACG CGT
TTA TTT GTC ACA AGA TTT GGG C); 5K: (CCG GTC TAG ACA CCA TGG
AAG CCC CAG CGC AC); 3K: (TGC GTC GAC TTA CTA ACA CTC TCC CCT
GTT G). The primers 3F and 3K contain Mul I and Sal I sites and the
primers 5F and 5K contain Not I, Nhe I and Xba I sites, respectively.
The SF and SK sequenceswere fused into pGEM-T to yield pGEM-T–
SK and pGEM-T–SF. After the blue-white colony screening and
restriction enzyme, the pGEM-T–SK was digested with Sal I and Xba
I and SK was subcloned into pIRES to yield pIRES–SK. The pGEM-T–SF
was digested with Mul I and Nhe I and SF was subcloned into pIRES–
SK to yield pIRES–SK–SF (pIRES-HB). It also is characterized by blue-
white colony screening and restriction enzyme analysis.
Subsequently, to construct the heavy chain and light chain
expression virus shuttle plasmid, the pIRES-HB was digested with
Not I and Sal I, and subcloned into the Sal I–Not I sites of pXXUF1 (a
generous gift from Dr Xiao Xiao) to yield pXXUF1-HB.
AAV vector production
AAV vectors were generated by triple plasmid transfect ion of 293
cells (Xiao et al., 1998). For pseudo-typed AAV vector production, the
adenovirus helper plasmids XX6 (Xiao et al., 1998), and XX12 were
identical. The pseudo-typed AAV packaging plasmids contained I
serotype-speciﬁc capsid gene (Gao et al., 2002; Rutledge et al., 1998).
Vector plasmid pXXUF1-HB contains HB DNA driven by the CMV
promoter. Thus, the resultant AAV viral particles contained the
identical AAV vector DNA cassette of HB gene that was packaged by I
serotype capsids. Viruses were puriﬁed through CsCl gradient
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were determined by a standard dot-blot assay (Snyder et al., 1996).
Animals and vector administration
Housing and handing of the mice are in compliance with the
National Institutes of Health and institutional guidelines and
approved by the Institutional Animal Care and Use Committee of
Huazhong University of Science and Technology. In detail, eight- to
twelve-week C57BL/6 adult mice were purchased from Institute of
Organ Transplantation, Tongji Medical College. All animals received
immunosuppressant CSA at 5 mg/kg/d till the end of the experiment.
AAV serotype 1 (1011 genome copies/animal) was used to code for HB
or GFP. For intramuscular (i.m.) injection in mice, 200 ml of viral
solution was slowly injected with a U-100 insulin syringe. 100 ml of
viral solution was injected into both left and right hind legs.
Vector perfusion via portal vein was performed as follows. All
animals received pentobarbital (Narcoren; 40 mg/kg i.p.) and
piritramid (Dipidolor, 15 mg/kg i.m.) for anesthesia. The rAAV was
left in liver by blocking superior vena cava and inferior vena cava for
10 min.
Detection of transgene expression
To examine the expression of the enhanced green ﬂuorescent
protein, GFP, we killed the mice and prepared 6-mm cryosections of
various tissues for microscopic examination. GFP expressions were
observed using a Nikon TE-300 ﬂuorescent microscope with Spot
digital camera. For quantitative analysis of the intensity levels of
GFP expression, 12-bit monochrome photographs were taken, and
the exposure conditions were maintained throughout the experi-
ments to keep the data comparable. The average intensities were
analyzed by the Image J software (version 1.37) from Universal
Imaging Corporation and the average grade level was used as the
unit of ﬂuorescence intensity in tissues. The intensity of GFP
expression was presented as the obtained intensity minus the
background intensity of corresponding tissues from mice without
AAV vector treatment.
Detection of HB expression by muscular injection
ELISA
To detect the HB in serum, approximately 500 ml blood was drawn
from the tail vein and sera were collected after coagulation and
centrifugation. All the samples were subjected to measurements of HB
levels in sera. The serum sample was assayed using a radioimmu-
noassay kit (Abbott Laboratories, Chicago, IL).
Western blot
The proteins of liver tissues separated by SDS-PAGE were electro-
transferred to polyvinylidene diﬂuoride (PVDF) membrane (Millipore,
Massachusetts, USA) by themethod of Sambrook et al. (1989) (Bio-Rad
Tran blot SD; 15 V, 30 min). The membrane was incubated with HRP
(horseradish peroxidase)-conjugated goat antihuman Fab speciﬁc IgG
(Sigma, St. Louis, USA, 1:1000 dilution in 1% albumin/PBS-buffer) for
1 h at 37 °C. The protein bands were visualized by OPD (Promega,
Madison, USA) staining.
Immunohistochemistry
For detection of HB expression, tissue sections from frozen
biopsies were ﬁxed for 10 min at room temperature in PBS with 4%
paraformaldehyde. Sections were then washed with 0.1% saponin in
PBS and incubated with mouse antihuman Fab IgG for 1 h. Sections
were next incubated with goat anti-mouse IgG conjugated withbiotin followed by streptavidin–horseradish peroxidase (HRP). Endo-
genous peroxidase activity was blocked with 0.3% H2O2 prior to
incubation of HRP. Tissue biotin was blocked by treatment with
avidin and then biotin (Dako, Carpentaria, CA). The color was
developed with DAB (Dako). Samples stained only with goat anti-
mouse IgG were used as controls.
Tree shrews study
Twenty tree shrews, Tupaia belangeri chinenesis, which came from
Kunming animal research school, Chinese academy of science, and
weighted from 100 g to 120 g were used in this study. These animals
had not been previously inoculated with any HBV-containing
materials and were seronegative for all HBV-associated serological
markers. The study tree shrews were given an intramuscular injection
of 5×1011 v.g. of rAAV-HB, while the control animals were given the
same dose of rAAV-GFP. Two weeks later, 105 copies/ml of human sera
containing adr subtype of wild type HBV (contributed by Dr Shihui
Song), were inoculated intravenously into the animals. Serum samples
taken from the tree shrews were monitored for levels of HB, HBsAg,
antibodies to HBcAg and HBsAg, HBV-DNA and liver enzymes such as
alanine aminotransferase and aspartate aminotransferase. The HB
levels were detected by the serum samples of the tree shrews only
treated with rAAV-HB. Serological assays of the HBV antigens and HB,
anti-HBV antibodies were done using commercial solid-phase radio-
immunoassay kits (Abbott Laboratories, USA). HBV-DNA was done
using commercial PCR-Fluorescence quantity diagnostic kits (Kehua
Bio-engineering, China).
Immunohistochemical staining of human tissues by HB
A standard, indirect immunohistochemical staining method was
performed. Brieﬂy, liver biopsy samples from HBV-infected indivi-
duals were ﬁxed, dehydrated, and embedded in parafﬁn. Parafﬁn-
embedded samples were thin sectioned serially using a microtome,
deparafﬁnized in xylene, rehydrated with a graded ethanol series, and
covered with 5% (v/v) goat serum in PBS to block nonspeciﬁc
adsorption. Sections were incubated with each puriﬁed anti-HBs-Fab
antibody, HB for 60min at room temperature. After washing with PBS,
the sections were incubated with HRP-conjugated goat anti-human
Fab IgG (Sigma, A0293) for 60 min at room temperature. The
peroxidase reactions were developed with diaminobenzidine. Subse-
quently, the sections werewashed, and stainedwithmethyl green. For
the positive control, the commercial monoclonal mouse anti-HBs IgG
(Tapp and Jones, 1977) was used.
Micro-cytotoxicity assay
The 3B hepatocellular carcinoma cells (from the China Center for
Type Culture Collection, Wuhan, China) that show surface expression
of HBs antigens were cultured to conﬂuence in a 72-well plate (103/
well) and incubated with puriﬁed HB antibodies (2 mg/ml) at 37 °C for
1 h, and then with antihuman Ig Fab goat antibody (Sigma). After
washing with ice-cold PBS, the cells were incubated with rabbit
complement and then with the solution supplied in Cell Counting Kit
8 (DOJIN, Tokyo, Japan). The proportion of viable cells wasmeasured in
terms of OD450 according to the manufacturer's protocol. The human
IgG1 (Sigma-Aldrich) was used for positive control and nonspeciﬁc
antibody in the negative control.
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